Pharmacological treatment of challenging neuropsychiatric symptoms of dementia

Journal of Pharmacy Practice and Research

Volumn 35, Issue 3, 2005, Pages 228-234

  Woodward, Michael C ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOZAPINE; DIAZEPAM; DIPHENHYDRAMINE; DONEPEZIL; FLUOXETINE; GABAPENTIN; HALOPERIDOL; LITHIUM; LORAZEPAM; MEMANTINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE; OXAZEPAM; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THIORIDAZINE; TRAZODONE; UNINDEXED DRUG; ZIPRASIDONE;

AGGRESSION; AGITATION; ASTHMA; BRADYCARDIA; CLINICAL TRIAL; CONSTIPATION; DEATH; DEMENTIA; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; HYPONATREMIA; INFORMED CONSENT; INSOMNIA; MONITORING; MORTALITY; NAUSEA; NEUROPSYCHIATRY; NURSING; PATIENT MONITORING; PEPTIC ULCER; PSYCHOSIS; REVIEW; RISK ASSESSMENT; SIDE EFFECT; STROKE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 27644552636     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2005.tb00348.x     Document Type: Review

References (128)

1. Access Economics. Dementia estimates and projections: Australian states and territories. Report for Alzheimer's Australia. Brisbane: Access Economics; 2005.
2. Suh G-K, Seung KK. Behavioural and psychological signs and symptoms of dementia (BPSD) in anti-psychotic-naive Alzheimer's disease patients. Int Psychogeriatr 2004; 16: 337-50.
3. Teri L, Rabins P, Whitehouse P, Berg L, Reisberg B, Sunderland T, et al. Management of behavioural disturbance in Alzheimer disease: current knowledge and future directions. Alzheimer Dis Assoc Disord 1992; 6: 77-88.
4. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioural disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157: 708-14.
5. Mega MS, Cummings JL, Fiorello T, Gombein J. The spectrum of behavioural changes in Alzheimer's disease. Neurology 1996; 46: 130-5.
6. Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. JAMA 2002; 288: 1475-83.
7. Sink KM, Covinsky KE, Newcomer R, Yaffe K. Ethnic differences in the prevalence and pattern of dementia-related behaviours. J Am Geriatr Soc 2004; 52: 1277-83.
8. Feldman H, Scheltens P, Scarpini E, Hermann N, Mesenbrink P, Mancione L, et al. Behavioral symptoms in mild cognitive impairment. Neurology 2004; 62: 1199-201.
9. Hart DJ, Craig D, Compton SA, Critchlow S, Kerrigan BM, McIlroy SP, et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer's disease. Int J Geriatr Psychiatry 2003; 18: 1037-42.
10. Black W, Almeida OP. A systematic review of the association between the behavioral and psychological symptoms of dementia and burden of care. Int Pschogeriatr 2004; 16: 295-315.
11. Nagaratnam N, Lewis-Jones M, Scott D, Palazzi L. Behavioral and psychiatric manifestations in dementia patients in a community: caregiver burden and outcome. Alzheimer Dis Assoc Disord 1998; 12: 330-4.
12. Coen RF, Swanwick GR, O'Boyle CA, Coakley D. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12: 331-6.
13. Clyburn LD, Stones MJ, Hadjistavropoulos T, Tuokko H. Predicting caregiver burden and depression in Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci 2000; 55: S2-S13.
14. Phillips VL, Diwan S. The incremental effect of dementia-related problem behaviors on the time to nursing home placement in poor, frail, demented older people. J Am Geriatr Soc 2003; 51: 188-93.
15. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990; 147: 1049-51.
16. Stern Y, Tang MX, Albert MS, Brandt J, Jacobs DM, Boll K, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 277: 806-12.
17. Yaffe K, Fox P, Newcomer R, Sands L, Lindquist K, Dane K, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA 2002; 287: 2090-7.
18. Beeri MS, Werner P, Davidson M, Noy S. The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. Int J Geriatr Psychiatry 2002; 17: 403-8.
19. Gruber-Baldini AL, Boustani M, Sloane PD, Zimmerman S. Behavioral symptoms in residential care/assisted living facilities: prevalence, risk factors, and medication management. J Am Geriatr Soc 2004; 52: 1610-17.
20. Snowdon J, Miller R, Vaughan R. Behavioural problems in Sydney nursing homes. Int J Geriatr Psychiatry 1996; 11: 535-41.
21. Brodaty H, Draper B, Saab D, Low L-F, Richards V, Paton H, et al. Psychosis, depression and behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry 2001; 16: 504-12.
22. Steinberg M, Tschanz JT, Corcoran C, Steffens DC, Norton MC, Lyketsos CG, et al. The persistence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry 2004; 19: 19-26.
23. Eustace A, Coen R, Walsh C, Cunningham CJ, Walsh JB, Coakley D, et al. A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int J Geriatr Psychiatry 2002; 17: 968-73.
24. Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, et al. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000; 55: 1460-7.
25. Low L-F, Brodaty H, Draper B. A study of premorbid personality and behavioural and psychological symptoms of dementia in nursing home residents. Int J Geriatr Psychiatry 2002; 17: 779-83.
26. Kolanowski AM, Whall AL. Life span perspective of personality in dementia. Image J Nurs Sch 1996; 28: 315-20.
27. Sweet RA, Nimgaonkar VL, Devlin B, Lopez O, DeKosky ST. Increased familial risk of the psychotic phenotype of Alzheimer disease. Neurology 2002; 58: 907-11.
28. Scarmeas N, Brandt J, Albert M, Devanand DP, Marder K, Bell K, et al. Association between the APOE genotype and psychopathologic symptoms in Alzheimer's disease. Neurology 2002; 58: 1182-8.
29. Low L-F, Draper B, Brodaty H. The relationship between self-destructive behaviour and nursing home environment. Aging Mental Health 2004; 8: 29-33.
30. Hall KA, O'Connor DW. Correlates of aggressive behavior in dementia. Int Psychogeriatr 2004; 16: 141-58.
31. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry 2001; 9: 361-81.
32. Cohen-Mansfield J. Non-pharmacologic interventions for psychotic symptoms in dementia. J Geriatr Psychiatry Neurology 2003; 16: 219-24.
33. Teri L, Logsdon RG, Whall AL. Treatment for agitation in dementia patients: a behavioral management approach. Psychotherapy 1998; 35: 436-43.
34. Brodaty H, Green A, Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc 2003; 51: 657-64.
35. Politis AM, Vozzella S, Mayer LS, Onyike CU, Baker AS, Lyketsos CG. A randomized, controlled, clinical trial of activity therapy for apathy in patients with dementia residing in long-term care. Int J Geriatr Psychiatry 2004; 19: 1087-94.
36. Beattie ER, Algase DL, Song J. Keeping wandering nursing home residents at the table: improving food intake using a behavioral communication intervention. Aging Mental Health 2004; 8: 109-16.
37. Sherratt K, Thornton A, Hatton C. Music interventions for people with dementia: a review of the literature. Aging Mental Health 2004; 8: 3-12.
38. Heim C, Nair BK, Mowbray D, Tavender J. Effects of ambient baroque music on patients with dementia. Aust J Ageing 2003; 22: 211-3.
39. Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, et al. Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003; 290: 2015-22.
40. Skjerve A, Bjorvatn B, Holsten F. Light therapy for behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry 2004; 19: 516-22.
41. Agostini JV, Han L, Tinetti ME. The relationship between number of medications and weight loss or impaired balance in older adults. J Am Geriatr Soc 2004; 52: 1719-23.
42. Kennerflalk A, Ruigomez A, Wallander MA, Wilhelmsen L, Johansson S. Geriatric drug therapy and healthcare utilization in the United Kingdom. Ann Pharmacother 2002; 36: 797-803.
43. Roberts M, King M, Stokes J, Lynne T, Bomer C, McCarthy S, et al. Medication prescribing and administration in nursing homes. Age Ageing 1998; 27: 385-92.
44. Burgess CL, Holman CD, Sam AG. Adverse drug reactions in older Australians, 1981-2002. Med J Aust 2005; 182: 267-70.
45. Gurwitz JH, Field TS, Avorn J, McCormick D, Jain S, Eckler M, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000; 109: 87-94.
46. Woodward MC. Deprescribing: achieving better health outcomes for older people through reducing medications. J Pharm Pract Res 2003; 33: 323-8.
47. Woodward MC. Hypnotics: options to help your patients stop. Aust Fam Physician 2000; 29: 939-44.
48. Sloane PD, Gruber-Baldini AL, Zimmerman S, Roth M, Watson L, Boustani M, et al. Medication undertreatment in assisted living settings. Arch Intern Med 2004; 164: 2031-7.
49. Peters NL. Snipping the thread of life-antimuscarinic side effects of medications in the elderly. Arch Int Med 1989; 149: 2414-20.
50. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA. The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc 2004; 52: 2082-7.
51. Fonda D. Problems associated with prescribed drug use in the elderly. Aust J Hosp Pharm 1991; 21: 127-30.
52. McLean AJ, Le Couteur DG. Aging biology and geriatric clinical pharmacology. Pharmacol Rev 2004; 56: 163-84.
53. Pitkala KH, Laurila JV, Strandberg TE, Tilvis RS. Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards. Int Psychogeriatr 2004; 16: 61-74.
54. Bronskill SE, Anderson GM, Sykora K, Wodchis WP, Gill S, Shulman KI, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc 2004; 52: 749-55.
55. Brodaty H, Ames D, Snowdon J, Woodward MC, Kirwan J, Clarnette R, et al. A randomized placebo controlled trial of risperidone for the treatment of agitation and psychosis of dementia. J Clin Psychiatry 2003; 64: 134-43.
56. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial: Risperidone Study Group. J Clin Psychiatry 1999; 60: 107-15.
57. De Deyn PP, Rabheru K, Rasmussen A, Bocksberger JP, Dautzenberg PL, Eriksson S, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53: 946-55.
58. Rabinowitz J, Katz IR, De Deyn PP, Brodaty H, Greenspan A, Davidson M. Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidone. J Clin Psychiatry 2004; 65: 1329-34.
59. De Deyn PP, Katz IR, Brodaty H, Lyons B, Greenspan A, Burns A. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double blind trials in nursing home residents treated with risperidone. Clin Neurol Neurosurg. In press.
60. Frank L, Kleinman L, Ciesla G, Rupnow MF, Brodaty H. The effect of risperidone on nursing burden associated with caring for patients with dementia. J Am Geriatr Soc 2004; 52: 1449-55.
61. Wancanta J. Efficacy of risperidone for treating patients with behavioral and psychological symptoms of dementia. Int Psychogeritr 2004; 16: 107-15.
62. Suh GH, Son HG, Ju YS, Jcho KH, Yeon BK, Shin YM, et al. A randomized, double blind, crossover comparison of risperidone and haloperidol in Korean dementia patients with behavioral disturbances. Am J Geriatr Psychiatry 2004; 12: 509-16.
63. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia:a review of the evidence. JAMA 2005; 293: 596-608.
64. Street JS, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial: the HGEU Study Group. Arch Gen Psychiatry 2000; 57: 968-76.
65. Meehan KM, Wang H, David SR, Nisivoccia JR, Jones B, Beasley CM Jr, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26: 494-504.
66. De Deyn PP, Carrasco MM, Deberdt W, Jeandel C, Hay DP, Feldman PD, et al. Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004; 19: 115-26.
67. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64.
68. Ballard C, Margallo-Lana M, Juszczak E, Douglas S, Swann A, Thomas A, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double blind placebo controlled trial. BMJ 2005; 330: 874-7.
69. Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis in parkinsonian patients. Mov Disord 2004; 19: 831-3.
70. Madhusoodanan S, Breener R, Cohen CI. Role of atypical antipsychotics in the treatment of psychosis and agitation associated with dementia. CNS Drugs 1999; 12: 135-50.
71. Juncos JL, Roberts VJ, Evatt ML, Jewart RD, Wood CD, Potter LS, et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov Disord 2004; 19: 29-35.
72. Alexopoulos GS, Streim J, Carpenter D, Docherty JP. Using antipsychotic agents in older patients. J Clin Psychiatry 2004; 65 (suppl. 2): 5-99.
73. Jeste DV, Okamoto A, Napolitano J, Kane JM, Martinez RA. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000; 157: 1150-5.
74. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris MJ, Caligiuri MP. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47: 716-9.
75. Fernandez HH, Trieschmann ME, Burke MA, Friedman JH. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies. J Clin Psychiatry 2002; 63: 513-5.
76. McKeith IG, Ballard CG, Harrison RW. Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995; 346: 699.
77. Walker Z, Grace J, Overshot R, Satarasinghe S, Swan A, Katona CL, et al. Olanzapine in dementia with Lewy bodies: clinical study. Int J Geriatr Psychiatry 1999; 14: 459-66.
78. Cavazzoni P, Young C, Polzer J, et al. Incidence of cerebrovascular adverse events and mortality during antipsychotic clinical trials of elderly patients with dementia. Proceedings of the 44th Annual New Clinical Drug Evaluation Unit 2004. June 1-4, Phoenix, Arizona, USA.
79. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004; 170: 1395.
80. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular adverse events in dementia trials. CMAJ 2002; 167: 1269-70.
81. Herrmann N, Lanctôt KL. Do atypical antipsychotics cause stroke? CNS Drugs 2005; 19: 91-103.
82. FDA Public Health Advisory. Deaths with antipsychotics in elderly patients with behavioural disturbances. Available from 〈www.fda.gov/cder/ drug/advisory/antipsychotics.htm〉. Accessed 15 April 2005.
83. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new-onset diabetes. Biol Psychiatry 1998; 44: 778-83.
84. Katz IR, Rupnow M, Kozma C, Schneider L. Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial. Am J Geriatr Psychiatry 2004; 12: 499-508.
85. Mulsant BH, Gharabawi GM, Bossie CA, Mao L, Martinez RA, Tune LE, et al. Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine. J Clin Psychiatry 2004; 65: 1708-14.
86. Allard J, Artero S, Ritchie K. Consumption of psychotropic medication in the elderly: a re-evaluation of its effect on cognitive performance. Int J Geriatr Psychiatry 2003; 18: 874-8.
87. Halbreich U, Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr Bull 1996; 22: 447-54.
88. Alvir JM, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-7.
89. 2 binding in the cortex. Neurology 2001; 57: 805-11.
90. Cummings JL, Schneider L, Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry 2004; 161: 532-8.
91. Suh DC, Arcona S, Thomas SK, Powers C, Rabinowicz AL, Shin H, et al. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine. Drugs Aging 2004; 21: 395-403.
92. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
93. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24.
94. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297-305.
95. Areosa Sastre A, Sherriff F, McShane R. Memantine for dementia. Cochrane Database of Systematic Reviews. 2005, Issue 3.
96. Porsteinsson AP, Tariot PN, Erb B, Cox C, Smith E, Jakimovich L, et al. Placebo-controlled study of divalproex sodium for agitation in dementia. Am J Geriatr Psychiatry 2001; 9: 58-66.
97. Tariot PN, Schneider LS, Mintzer J, et al. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial. Curr Ther Res Clin Exp 2001; 62: 51-67.
98. Sival RC, Haffmans PM, Jansen PA, Duursma SA, Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia: a randomized placebo controlled clinical trial. Int J Geriatr Psychiatry 2002; 17: 579-85.
99. Tariot PN, Erb R, Podgorski CA, Cox C, Patel S, Jakimovich L, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155: 54-61.
100. Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral problems in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psychiatry 2001; 9: 400-5.
101. Sival RC, Duivenvoorden HJ, Jansen PA, Haffmans PM, Duursma SA, Eikelenboom P. Sodium valproate in aggressive behaviour in dementia: a twelve-week open label follow-up study. Int J Geriatr Psychiatry 2004; 19: 305-12.
102. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Gabapentin for the treatment of behavioural alterations in dementia: a preliminary 15-month investigation. Drugs Aging 2003; 20: 1035-40.
103. Pollock BG, Mulsant BH, Rosen J, Sweet RA, Mazumdar S, Bharucha A, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry. 2002; 159: 460-5.
104. Finkel SI, Mintzer JE, Dysken M, Krishnan KR, Burt T, McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psychiatry 2004; 19: 9-18.
105. Lyketsos CG, DelCampo L, Steinberg M, Miles O, Steele LD, Baker AS, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60: 737-46
106. Auchus AP, Bissey-Black C. Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1997; 9: 591-3.
107. Teri L, Logsdon RG, Peskind E, Raskind M, Weiner MF, Tractenberg RE, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurology 2000; 55: 1271-8.
108. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004; 17: 355-9.
109. Coccaro EF, Kramer E, Zemishlany Z, Thorne A, Rice CM 3rd, Giordani B, et al. Pharmacological treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147: 1640-5.
110. Covington JS. Alleviating agitation, apprehension, and related symptoms in geriatric patients: a double blind comparison of phenothiazine and a benzodiazepine. South Med J 1975; 68: 719-24.
111. Kirven LE, Montero EF. Comparison of thioridazine and diazepam in the control of non-psychotic symptoms associated with senility: double blind study. J Am Geriatr Soc 1973; 21: 546-51.
112. Woodward MC. Hypnosedatives in the elderly. A guideline to appropriate use. CNS Drugs 1999; 11: 263-76.
113. Tamblyn R, Abrahamowicz M, du Berger R, McLeod P, Bartlett G. A 5-year prospective assessment of the risk associated with individual benzodiazepines and doses in new elderly users. J Am Geriatr Soc 2005; 53: 233-41.
114. Wagner AK, Zhang F, Soumerai SB, Walker AM, Gurwitz JH, Glynn RS, et al. Benzodiazepine use and hip fractures in the elderly. Who is at greatest risk? Arch Intern Med 2004; 164: 1567-72.
115. Kyomen HH, Satlin A, Hennen J, Wei JY. Estrogen therapy and aggressive behavior in elderly patients with moderate-to-severe dementia: results from a short-term, randomised, double-blind trial. Am J Geriatr Psychiatry 1999; 7: 339-48.
116. Haussermann P, Goecker D, Beier K, Schroeder S. Low-dose cyproterone acetate treatment of sexual acting out in men with dementia. Int Psychogeriatr 2003; 15: 181-6.
117. Buffum MD, Miaskowski C, Sands L, Brod M. A pilot study of the relationship between discomfort and agitation in patients with dementia. Geriatric Nurs 2001; 22: 80-85.
118. Geda YE, Rummans TA. Pain: cause of agitation in elderly individuals with dementia. Am J Psychiatry 1999; 156: 1662-3.
119. Scherder E, Oosterman J, Swaab D, Herr K, Doms M, Ribbe M, et al. Recent developments in pain in dementia. BMJ 2005; 330: 461-4.
120. Manfredi PL, Breuer B, Wallenstein S, Stegmann M, Bottomley G, Libow L. Opioid treatment for agitation in patients with advanced dementia. Int J Geriatr Psychiatry 2003; 18: 700-5.
121. Kurle S, Cameron I. The role of morphine in late stage dementia. Medical Observer 1995, 7 July.
122. Colenda CC. Buspirone in the treatment of agitated demented patients. Lancet 1988; 1: 1169.
123. Tiller JW, Dakis JA, Shaw JM. Short-term buspirone treatment in disinhibition with dementia [letter]. Lancet 1988; 2: 510.
124. Sakauye KM, Camp CJ, Ford PA. Effects of buspirone on agitation associated with dementia. Am J Geriatr Psychiatry 1993; 1: 82-4.
125. Peskind ER, Tsuang DW, Bonner LT, Pascualy M, Riekse RG, Snowden MB, et al. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer's disease: a placebo-controlled study. Alzheimer Dis Assoc Disord 2005; 19: 23-8.
126. van Reekum R, Clarke D, Conn D, Herrmann N, Eryavec G, Cohen T, et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr 2002; 14: 197-210
127. Ruths S, Straand J, Nygaard HA, Bjorvatn B, Pallesen S. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. J Am Geriatr Soc 2004; 52: 1737-43.
128. Woodward MC and working group. Dementia can it be prevented? Melbourne: Alzheimer Australia; 2005.